Thyroid Function Test Market Size & Share Analysis - Growth Trends & Forecasts (2025 - 2030)

The Thyroid Function Test Market Report is Segmented by Test (TSH Test, Free/Total T4 Test, Free/Total T3 Test, and More), Technique (Immunoassay, Rapid Point-Of-Care Tests, and More), Sample Type (Serum/Plasma, and More), End User (Hospital, Diagnostic Laboratory, Other End Users, and More), and Geography (North America, Europe, Asia-Pacific, and More). The Market Forecasts are Provided in Terms of Value (USD).

Thyroid Function Test Market Size and Share

Image © Mordor Intelligence. Reuse requires attribution under CC BY 4.0.

Compare market size and growth of Thyroid Function Test Market with other markets in Healthcare Industry

Thyroid Function Test Market Analysis by Mordor Intelligence

The thyroid function testing market is valued at USD 1.89 billion in 2025 and is projected to reach USD 2.47 billion by 2030, posting a CAGR of 5.53% during the forecast period. Rising global thyroid disease prevalence, an expanding elderly population, and the spread of newborn screening programs anchor this growth. Technology integration—especially high-sensitivity third-generation immunoassays, emerging mass-spectrometry methods, and AI-guided reflex-testing algorithms—elevates diagnostic accuracy while easing the workload created by endocrinologist shortages that affect 70% of US counties. Regulatory changes such as the US FDA’s 2024 framework for laboratory-developed tests introduce higher compliance costs yet promise greater standardization[1]US Food and Drug Administration, “Laboratory Developed Tests Final Rule,” fda.gov. Price transparency laws and bundled-contract negotiations are shifting volumes toward lower-cost independent laboratories, intensifying competition but expanding patient access.

Key Report Takeaways

  • By test type, the TSH assay held 42.86% of thyroid function testing market share in 2024; Anti-TPO/Anti-TG antibody tests are poised for a 7.56% CAGR to 2030.
  • By technique, immunoassay methods accounted for 60.23% share of the thyroid function testing market size in 2024, whereas point-of-care tests will grow at an 8.86% CAGR.
  • By end user, hospitals captured 41.78% share of the thyroid function testing market size in 2024, while diagnostic laboratories are advancing at an 8.34% CAGR.
  • By geography, North America led with 34.89% revenue share in 2024, while Asia-Pacific is projected to expand at a 6.89% CAGR through 2030.

Segment Analysis

By Test: TSH Dominance Faces Antibody Test Disruption

The TSH assay held a 42.86% slice of the thyroid function testing market in 2024, reflecting guideline preference for a sensitive first-line screen. Anti-TPO and Anti-TG antibody assays, while smaller in absolute volume, are expanding at 7.56% CAGR as autoimmune thyroiditis recognition accelerates. Turbo TSI bioassays cut turnaround time from days to hours, and point-of-care antibody kits deliver actionable results inside 10 minutes. Emerging mass-spectrometry panels gain favor in complex cases, promising higher specificity and lower interference, thereby broadening the thyroid function testing market.

Free/total T4 assays remain indispensable for dose titration and differential diagnosis, whereas free/total T3 holds a niche role given low prevalence of isolated T3 toxicosis. Specialized markers—thyroglobulin for differentiated thyroid cancer follow-up and calcitonin for medullary carcinoma—provide incremental revenues but do not materially shift overall thyroid function testing market size. AI-based pattern-recognition tools now help clinicians interpret multi-analyte profiles, reducing diagnostic ambiguity and encouraging wider antibody-panel adoption.

Image © Mordor Intelligence. Reuse requires attribution under CC BY 4.0.

Note: Segment shares of all individual segments available upon report purchase

By Technique: Immunoassay Leadership Challenged by POCT Innovation

Immunoassays controlled 60.23% of 2024 revenues, leveraging automated chemiluminescent and ELISA platforms that process thousands of samples per shift. Growth continues but moderates as decentralized care models fuel an 8.86% CAGR for point-of-care formats. Lateral-flow strips using gold nanoshells cut TSH detection thresholds to 0.16 µIU/mL, matching lab-grade sensitivity. Digital immunoassays provide cloud-connected results for remote monitoring, widening the thyroid function testing market.

Mass spectrometry adoption rises within reference labs seeking unparalleled specificity, especially for free hormones where protein binding skews immunoassays. Fluorescence polarization and electrochemiluminescence remain specialty tools in research. COVID-19 heightened appreciation for rapid, minimally attended diagnostics, a behavioral shift sustaining post-pandemic uptake of portable devices and reshaping investment priorities across the thyroid function testing industry.

By Sample Type: Serum Supremacy Yields to Capillary Innovation

Serum and plasma samples still constitute 72.46% of volume, favored for multiparameter panels and regulatory familiarity. Yet capillary blood testing posts a 7.45% CAGR on convenience benefits. Correlation coefficients exceed 0.97 for TSH and free T4 when comparing finger-stick with venous draws, reassuring clinicians of clinical equivalence [endocrinesociety.org]. Dried blood spots streamline newborn programs in remote settings, while smartphone-linked readers transform self-testing into actionable care pathways. As telehealth normalizes, capillary sampling expands overall thyroid function testing market size by recruiting previously undertested populations.

Image © Mordor Intelligence. Reuse requires attribution under CC BY 4.0.

By End User: Hospital Dominance Shifts Toward Laboratory Efficiency

Hospitals generated 41.78% of 2024 revenue, leveraging integrated electronic records and immediate turnaround for acute care. Nonetheless, their higher cost structure—2-6 times that of independent labs—drives payer migration to central laboratories posting an 8.34% CAGR. Price transparency rules expose variability up to 600% for identical thyroid panels, intensifying the push toward lower-cost channels labcorp. Consolidation among reference labs enhances bargaining power, while specialized thyroid centers adopt mass-spectrometry and AI analytics to carve differentiation. Home-testing providers ride rising consumer engagement and remote-care models, adding new demand strata within the thyroid function testing market.

Geography Analysis

North America retained the largest regional share at 34.89% in 2024, propelled by broad insurance coverage, high disease awareness, and sophisticated lab infrastructure. Endocrinologist shortages in 70% of US counties, however, risk pockets of under-service, prompting wider deployment of AI triage tools and tele-endocrinology consults. Price-benchmarking regulations spur health systems to reroute non-urgent panels to independent labs, altering channel mix but sustaining overall thyroid function testing market growth.

Asia-Pacific is the fastest-growing arena at 6.89% CAGR. India’s 11% hypothyroidism prevalence signals a substantial screening opportunity [ijmedicine.com]. China’s rising thyroid cancer incidence and large population base fuel volume, while Japan’s rapidly aging society drives routine monitoring. Government-backed newborn screening expansions in Thailand and elsewhere demonstrate near-universal coverage feasibility, unlocking predictable volumes and elevating regional thyroid function testing market size. Regulatory heterogeneity and reimbursement gaps remain challenges, yet digital health investments and public–private lab partnerships offset barriers.

Europe shows steady but slower expansion, anchored by universal health systems and stringent clinical guidelines. Budget constraints encourage centralized procurement and bundled contracts, favoring cost-efficient suppliers. Regulatory realignment post-Brexit adds complexity, yet established quality standards sustain clinician confidence. Middle East & Africa and South America emerge as longer-term growth pockets as healthcare infrastructure matures. Mobile testing units and telehealth platforms help overcome geographic obstacles, extending reach of the thyroid function testing market into underserved locales.

Thyroid Function Test Market
Image © Mordor Intelligence. Reuse requires attribution under CC BY 4.0.

Competitive Landscape

The thyroid function testing market is moderately consolidated. Abbott, Roche, and Siemens Healthineers leverage broad installed bases, integrated platforms, and service contracts to lock in laboratories. The FDA’s 2024 LDT rule shifts compliance burden toward larger firms with regulatory muscle, potentially thinning smaller outfits. Nonetheless, innovation windows remain: Polaris DX’s EUR 2,250 (USD 2605.9) portable analyzer offers disruptive cost-to-serve economics; HEI Therapeutics progresses patent-protected home-monitoring solutions.

Strategic playbooks center on AI augmentation, mass-spectrometry differentiation, and point-of-care expansion. Midsize vendors pursue geographic partnerships to access fast-growing Asia-Pacific markets, while incumbents bolster menus with calcitonin, antibody, and reflex-algorithm add-ons. Acquisition pipelines target niche assay developers and cloud-analytics specialists, evidencing sustained deal flow even amid rising regulatory costs. Competitive intensity should remain moderate as installed-platform switching barriers and service reliability outweigh pure reagent price in purchasing decisions.

Thyroid Function Test Industry Leaders

  1. Abbott

  2. Siemens Healthineers

  3. Danaher Corporation (Beckman Coulter)

  4. F. Hoffmann-La Roche Ltd

  5. DiaSorin SpA

  6. *Disclaimer: Major Players sorted in no particular order
Thyroid Function Test Market
Image © Mordor Intelligence. Reuse requires attribution under CC BY 4.0.
Need More Details on Market Players and Competitors?
Download PDF

Recent Industry Developments

  • October 2024: Siemens Healthineers completed verification of the Atellica DL IM1600 analyzer for anti-TPO and anti-TG detection, confirming precision standards for autoimmune thyroid diagnosis.
  • August 2024: Labcorp reported hospital thyroid test prices running 2-6 times higher than independent labs, driving payers toward lower-cost channels.
  • June 2024: HEI Therapeutics filed a patent on a home monitoring system aimed at personalized hypothyroidism management.
  • June 2024: Roche introduced the Elecsys Calcitonin assay for medullary thyroid cancer on the cobas platform.

Table of Contents for Thyroid Function Test Industry Report

1. Introduction

  • 1.1 Study Assumptions & Market Definition
  • 1.2 Scope of the Study

2. Research Methodology

3. Executive Summary

4. Market Landscape

  • 4.1 Market Overview
  • 4.2 Market Drivers
    • 4.2.1 Rising Burden of Thyroid Disorders
    • 4.2.2 Aging Population Raises Routine Screening Volumes
    • 4.2.3 High-Sensitivity 3rd-Gen Immunoassays Improve Clinical Utility
    • 4.2.4 Government-Funded Newborn & Population Screening Programs
    • 4.2.5 Direct-To-Consumer At-Home Test Kits & Tele-Lab Services
    • 4.2.6 AI-Driven Reflex-Testing Algorithms Increase Test Orders
  • 4.3 Market Restraints
    • 4.3.1 Complex Interpretation & Biotin Interference Issues
    • 4.3.2 Shortage Of Endocrinologists Slows Diagnosis & Follow-Up
    • 4.3.3 Lab Test Price Compression from Bundled Contracts
    • 4.3.4 Guideline Push-Back Against Over-Screening & Over-Treatment
  • 4.4 Regulatory Landscape
  • 4.5 Porter's Five Forces Analysis
    • 4.5.1 Bargaining Power of Suppliers
    • 4.5.2 Bargaining Power of Buyers/Consumers
    • 4.5.3 Threat of New Entrants
    • 4.5.4 Threat of Substitute Products
    • 4.5.5 Intensity of Competitive Rivalry

5. Market Size & Growth Forecasts

  • 5.1 By Test
    • 5.1.1 TSH Test
    • 5.1.2 Free/Total T4 Test
    • 5.1.3 Free/Total T3 Test
    • 5.1.4 Anti-TPO/Anti-TG Antibody Tests
    • 5.1.5 Other Test
  • 5.2 By Technique
    • 5.2.1 Immunoassay (CLIA, ELISA, RIA)
    • 5.2.2 Rapid Point-of-Care Tests
    • 5.2.3 Mass Spectrometry
    • 5.2.4 Other Techniques
  • 5.3 By Sample Type
    • 5.3.1 Serum/Plasma
    • 5.3.2 Capillary Blood (Finger-prick)
    • 5.3.3 Dried Blood Spot
  • 5.4 By End User
    • 5.4.1 Hospital
    • 5.4.2 Diagnostic Laboratory
    • 5.4.3 Other End Users
  • 5.5 Geography
    • 5.5.1 North America
    • 5.5.1.1 United States
    • 5.5.1.2 Canada
    • 5.5.1.3 Mexico
    • 5.5.2 Europe
    • 5.5.2.1 Germany
    • 5.5.2.2 United Kingdom
    • 5.5.2.3 France
    • 5.5.2.4 Italy
    • 5.5.2.5 Spain
    • 5.5.2.6 Rest of Europe
    • 5.5.3 Asia-Pacific
    • 5.5.3.1 China
    • 5.5.3.2 Japan
    • 5.5.3.3 India
    • 5.5.3.4 Australia
    • 5.5.3.5 South Korea
    • 5.5.3.6 Rest of Asia-Pacific
    • 5.5.4 Middle East & Africa
    • 5.5.4.1 GCC
    • 5.5.4.2 South Africa
    • 5.5.4.3 Rest of Middle East & Africa
    • 5.5.5 South America
    • 5.5.5.1 Brazil
    • 5.5.5.2 Argentina
    • 5.5.5.3 Rest of South America

6. Competitive Landscape

  • 6.1 Market Concentration
  • 6.2 Market Share Analysis
  • 6.3 Company Profiles (includes Global-level Overview, Market-level Overview, Core Segments, Financials, Strategic Information, Market Rank/Share, Products & Services, Recent Developments)
    • 6.3.1 Abbott
    • 6.3.2 Zhengzhou Autobio Co., Ltd.
    • 6.3.3 bioMrieux SA
    • 6.3.4 Danaher Corporation (Beckman Coulter)
    • 6.3.5 DiaSorin SpA
    • 6.3.6 F. Hoffmann-La Roche Ltd
    • 6.3.7 Qualigen, Inc.
    • 6.3.8 QuidelOrtho Corporation
    • 6.3.9 Siemens Healthineers
    • 6.3.10 Thermo Fisher Scientific Inc.
    • 6.3.11 Werfen
    • 6.3.12 Boditech Med Inc.
    • 6.3.13 Ortho Clinical Diagnostics
    • 6.3.14 Mindray Bio-Medical Electronics
    • 6.3.15 Randox Laboratories
    • 6.3.16 Tosoh Corporation
    • 6.3.17 Diazyme Laboratories
    • 6.3.18 Sysmex Corporation
    • 6.3.19 PerkinElmer Inc.
    • 6.3.20 IBL-America
    • 6.3.21 Sekisui Diagnostics
    • 6.3.22 Euroimmun AG

7. Market Opportunities & Future Outlook

  • 7.1 White-space & Unmet-need Assessment
You Can Purchase Parts Of This Report. Check Out Prices For Specific Sections
Get Price Break-up Now

Global Thyroid Function Test Market Report Scope

Thyroid function tests are a series of blood tests used to determine the condition of the thyroid gland, whether it is working properly, and diagnose hyperthyroidism and hypothyroidism. The general tests include T3, T3RU, T4, and TSH hormones (secreted by thyroid glands), which measure the activities of the thyroid gland. The Thyroid Function Test Market is segmented by test (TSH Test, T4 Test, T3 Test, and other tests), end user (hospital, diagnostic laboratory, and other end users), and Geography (North America, Europe, Asia-Pacific, Middle East, and Africa, and South America). The market report also covers the estimated market sizes and trends for 17 countries across major regions globally. The report offers the value (USD) for the above segments.

By Test TSH Test
Free/Total T4 Test
Free/Total T3 Test
Anti-TPO/Anti-TG Antibody Tests
Other Test
By Technique Immunoassay (CLIA, ELISA, RIA)
Rapid Point-of-Care Tests
Mass Spectrometry
Other Techniques
By Sample Type Serum/Plasma
Capillary Blood (Finger-prick)
Dried Blood Spot
By End User Hospital
Diagnostic Laboratory
Other End Users
Geography North America United States
Canada
Mexico
Europe Germany
United Kingdom
France
Italy
Spain
Rest of Europe
Asia-Pacific China
Japan
India
Australia
South Korea
Rest of Asia-Pacific
Middle East & Africa GCC
South Africa
Rest of Middle East & Africa
South America Brazil
Argentina
Rest of South America
By Test
TSH Test
Free/Total T4 Test
Free/Total T3 Test
Anti-TPO/Anti-TG Antibody Tests
Other Test
By Technique
Immunoassay (CLIA, ELISA, RIA)
Rapid Point-of-Care Tests
Mass Spectrometry
Other Techniques
By Sample Type
Serum/Plasma
Capillary Blood (Finger-prick)
Dried Blood Spot
By End User
Hospital
Diagnostic Laboratory
Other End Users
Geography
North America United States
Canada
Mexico
Europe Germany
United Kingdom
France
Italy
Spain
Rest of Europe
Asia-Pacific China
Japan
India
Australia
South Korea
Rest of Asia-Pacific
Middle East & Africa GCC
South Africa
Rest of Middle East & Africa
South America Brazil
Argentina
Rest of South America
Need A Different Region or Segment?
Customize Now

Key Questions Answered in the Report

What is the current global thyroid function testing market size?

The thyroid function testing market is valued at USD 1.89 billion in 2025.

Which region is growing fastest?

Asia-Pacific is expanding at a 6.89% CAGR to 2030, driven by newborn screening and rising awareness.

Why are TSH tests still dominant?

Clinical guidelines position TSH as the first-line screen, giving it 42.86% market share in 2024.

How is AI transforming thyroid diagnostics?

AI-driven reflex-testing algorithms automate ordering and interpretation, improving accuracy and easing specialist shortages.

What regulatory change affects laboratories most?

The US FDA’s 2024 rule on laboratory-developed tests introduces significant compliance costs and tighter oversight.

Thyroid Function Test Market Report Snapshots